These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33116200)

  • 1. Amorphous solid dispersions of enzalutamide and novel polysaccharide derivatives: investigation of relationships between polymer structure and performance.
    Wilson VR; Lou X; Osterling DJ; Stolarik DF; Jenkins GJ; Nichols BLB; Dong Y; Edgar KJ; Zhang GGZ; Taylor LS
    Sci Rep; 2020 Oct; 10(1):18535. PubMed ID: 33116200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between amorphous solid dispersion in vivo absorption and in vitro dissolution: phase behavior during dissolution, speciation, and membrane mass transport.
    Wilson V; Lou X; Osterling DJ; Stolarik DF; Jenkins G; Gao W; Zhang GGZ; Taylor LS
    J Control Release; 2018 Dec; 292():172-182. PubMed ID: 30408553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fed- and Fasted-State Performance of Pretomanid Amorphous Solid Dispersions Formulated with an Enteric Polymer.
    Nguyen HT; Van Duong T; Jaw-Tsai S; Bruning-Barry R; Pande P; Taneja R; Taylor LS
    Mol Pharm; 2023 Jun; 20(6):3170-3186. PubMed ID: 37220082
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of Polymers with Enzalutamide Nanodroplets-Impact on Droplet Properties and Induction Times.
    Wilson VR; Mugheirbi NA; Mosquera-Giraldo LI; Deac A; Moseson DE; Smith DT; Novo DC; Borca CH; Slipchenko LV; Edgar KJ; Taylor LS
    Mol Pharm; 2021 Mar; 18(3):836-849. PubMed ID: 33539105
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.
    Indulkar AS; Lou X; Zhang GGZ; Taylor LS
    Mol Pharm; 2019 Mar; 16(3):1327-1339. PubMed ID: 30669846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Crystallization Inhibition Properties of Cellulose Esters and Ethers for a Group of Chemically Diverse Drugs: Experimental and Computational Insight.
    Mosquera-Giraldo LI; Borca CH; Parker AS; Dong Y; Edgar KJ; Beaudoin SP; Slipchenko LV; Taylor LS
    Biomacromolecules; 2018 Dec; 19(12):4593-4606. PubMed ID: 30376299
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pairwise polymer blends for oral drug delivery.
    Marks JA; Wegiel LA; Taylor LS; Edgar KJ
    J Pharm Sci; 2014 Sep; 103(9):2871-2883. PubMed ID: 24823790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Polymer Hydrophobicity on the Stability of Amorphous Solid Dispersions and Supersaturated Solutions of a Hydrophobic Pharmaceutical.
    Frank DS; Matzger AJ
    Mol Pharm; 2019 Feb; 16(2):682-688. PubMed ID: 30645134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-polymer-water interaction and its implication for the dissolution performance of amorphous solid dispersions.
    Chen Y; Liu C; Chen Z; Su C; Hageman M; Hussain M; Haskell R; Stefanski K; Qian F
    Mol Pharm; 2015 Feb; 12(2):576-89. PubMed ID: 25535667
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moisture-Induced Amorphous Phase Separation of Amorphous Solid Dispersions: Molecular Mechanism, Microstructure, and Its Impact on Dissolution Performance.
    Chen H; Pui Y; Liu C; Chen Z; Su CC; Hageman M; Hussain M; Haskell R; Stefanski K; Foster K; Gudmundsson O; Qian F
    J Pharm Sci; 2018 Jan; 107(1):317-326. PubMed ID: 29107047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissolution Performance of High Drug Loading Celecoxib Amorphous Solid Dispersions Formulated with Polymer Combinations.
    Xie T; Taylor LS
    Pharm Res; 2016 Mar; 33(3):739-50. PubMed ID: 26563205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigation into the Solid-State Properties and Dissolution Profile of Spray-Dried Ternary Amorphous Solid Dispersions: A Rational Step toward the Design and Development of a Multicomponent Amorphous System.
    Baghel S; Cathcart H; O'Reilly NJ
    Mol Pharm; 2018 Sep; 15(9):3796-3812. PubMed ID: 30020788
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase separation of supersaturated solution created from amorphous solid dispersions: Relevance to oral absorption.
    Kawakami K; Sato K; Fukushima M; Miyazaki A; Yamamura Y; Sakuma S
    Eur J Pharm Biopharm; 2018 Nov; 132():146-156. PubMed ID: 30253186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissolution of Danazol Amorphous Solid Dispersions: Supersaturation and Phase Behavior as a Function of Drug Loading and Polymer Type.
    Jackson MJ; Kestur US; Hussain MA; Taylor LS
    Mol Pharm; 2016 Jan; 13(1):223-31. PubMed ID: 26618718
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight into Amorphous Solid Dispersion Performance by Coupled Dissolution and Membrane Mass Transfer Measurements.
    Hate SS; Reutzel-Edens SM; Taylor LS
    Mol Pharm; 2019 Jan; 16(1):448-461. PubMed ID: 30521350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multidrug, Anti-HIV Amorphous Solid Dispersions: Nature and Mechanisms of Impacts of Drugs on Each Other's Solution Concentrations.
    Arca HÇ; Mosquera-Giraldo LI; Dahal D; Taylor LS; Edgar KJ
    Mol Pharm; 2017 Nov; 14(11):3617-3627. PubMed ID: 28872867
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dissolution and Solubility Enhancement of the Highly Lipophilic Drug Phenytoin via Interaction with Poly(N-isopropylacrylamide-co-vinylpyrrolidone) Excipients.
    Widanapathirana L; Tale S; Reineke TM
    Mol Pharm; 2015 Jul; 12(7):2537-43. PubMed ID: 26046484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of polymer type and drug dose on the in vitro and in vivo behavior of amorphous solid dispersions.
    Knopp MM; Chourak N; Khan F; Wendelboe J; Langguth P; Rades T; Holm R
    Eur J Pharm Biopharm; 2016 Aug; 105():106-14. PubMed ID: 27212472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Wetting Kinetics: an Alternative Approach Towards Understanding the Enhanced Dissolution Rate for Amorphous Solid Dispersion of a Poorly Soluble Drug.
    Verma S; Rudraraju VS
    AAPS PharmSciTech; 2015 Oct; 16(5):1079-90. PubMed ID: 25672820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tailoring supersaturation from amorphous solid dispersions.
    Li N; Taylor LS
    J Control Release; 2018 Jun; 279():114-125. PubMed ID: 29654798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.